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tumor tracking over the internal target volume
concept for stereotactic body radiation
therapy of pancreatic cancer
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Stephan Klöck1,2, Matthias Guckenberger1,2 and Stephanie Tanadini-Lang1,2
Abstract
Background: Radiotherapy for pancreatic cancer has twomajor challenges: (I) the tumor is adjacent to several critical
organs and, (II) the mobility of both, the tumor and its surrounding organs at risk (OARs). A treatment planning study
simulating stereotactic body radiation therapy (SBRT) for pancreatic tumors with both the internal target volume (ITV)
concept and the tumor tracking approach was performed. The two respiratory motion-management techniques were
compared in terms of doses to the target volume and organs at risk.
Methods andMaterials: Two volumetric-modulated arc therapy (VMAT) treatment plans (5 × 5 Gy) were created for
each of the 12 previously treated pancreatic cancer patients, one using the ITV concept and one the tumor tracking
approach. To better evaluate the overall dose delivered to the moving tumor volume, 4D dose calculations were
performed on four-dimensional computed tomography (4DCT) scans. The resulting planning target volume (PTV) size
for each technique was analyzed. Target and OAR dose parameters were reported and analyzed for both 3D and 4D
dose calculation.
Results: Tumor motion ranged from 1.3 to 11.2 mm. Tracking led to a reduction of PTV size (max. 39.2%) accompanied
with significant better tumor coverage (p < 0.05, paired Wilcoxon signed rank test) both in 3D and 4D dose calculations
and improved organ at risk sparing. Especially for duodenum, stomach and liver, the mean dose was significantly
reduced (p < 0.05) with tracking for 3D and 4D dose calculations.
Conclusions: By using an adaptive tumor tracking approach for respiratory-induced pancreatic motionmanagement,
a significant reduction in PTV size can be achieved, which subsequently facilitates treatment planning, and improves
organ dose sparing. The dosimetric benefit of tumor tracking is organ and patient-specific.
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Background
Pancreatic cancer is one of the most aggressive tumors
with high mortality rates. According to cancer mortality
statistics, for 2015 in European Union (EU) a total of
85300 pancreatic cancer deaths are predicted (42700
men and 42600 women), making it the fourth leading
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cause of cancer-related deaths for both genders in the
EU [1].
Surgery is generally considered the standard treatment
for patients with resectable pancreatic cancer (PC) while
standard-dose chemoradiation therapy and chemother-
apy alone are suitable in case of unresectable disease
[2]. Stereotactic body radiation therapy (SBRT) allows for
higher doses per fraction to the tumor than the conven-
tional radiotherapy with sharp dose gradients in a shorter
overall treatment time, and better dose sparing of adja-
cent organs at risk. It has been successful in the treatment
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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of thoracic tumors and has been used for intra-abdominal
sites, including pancreas [2–5]. Besides the patient com-
fort due to significantly shorter treatment times, addi-
tional advantages of SBRT include the possibility of being
better integrated into multidisciplinary treatment con-
cepts, significantly less bone marrow toxicity and shorter
interruption of full-dose chemotherapy [5]. SBRT for pan-
creatic tumors has been either delivered by traditional
linear accelerator [6, 7] or a robotic arm-mounted linear
accelerator [6, 8].
Radiotherapy for pancreatic cancer has two major chal-
lenges: (i) the tumor is proximal to several critical organs
such as duodenum, stomach, small intestine, kidneys, liver
and spinal cord, and (ii) the mobility of both the tumor
and its surrounding organs at risk (OARs). The duode-
num, which often lies immediately adjacent to pancreatic
tumors, is most commonly the organ that limits the max-
imum dose that can be delivered to the target [9].
As radiotherapy treatments become more and more
conformal, without a full understanding of the individ-
ualized tumor/organ motion, the target volume could
be under-dosed while the nearby OARs could be over-
dosed, resulting in the degradation of the overall treat-
ment effectiveness and accuracy. Several studies have
addressed the important aspect of pancreatic mobility
caused by respiration using different imaging modalities
such as magnetic resonance imaging (MRI) [9, 10], four-
dimensional computed tomography (4DCT) [11–14],
cone-beam computed tomography [15], fluoroscopy
[16, 17] and ultrasound [18]. They have shown that, on
average, the magnitude of pancreatic motion is largest
in the cranial-caudal (superior-inferior) direction and the
largest reported value among them was 24 ± 16 mm [10].
The implementation of multi-fraction SBRT has
demonstrated promising results with favorable tumor
control and toxicity rates [19] which might be further
improved using advanced motion management strategies
which lead to margin reduction and therefore PTV size
reduction.
Different strategies have been proposed to account
for respiratory motion [20, 21]: active breath-hold tech-
niques [22], abdominal compression techniques [23],
gating during end-expiration [24], motion-encompassing
methods (Internal Target Volume (ITV) concept) [25],
and respiration-synchronized techniques (tumor tracking
approach) [25]. Tumor tracking is an advanced motion
management strategy, which adjusts dynamically the
treatment beam [26–28] or the patient position [29, 30] to
the tumor motion.
Currently, most clinics use the ITV concept, which
accounts for the whole tumor motion resulting in broad
safety margins. However, among the aforementioned
motion management methods, the tumor tracking is rec-
ognized as an advanced method of managing respiratory
motion reducing the size of the planning target volume
(PTV). This might lead to improved targeting and bet-
ter tumor control while minimizes the radiation-induced
toxicity to normal tissue. Real-time tracking of the pan-
creatic target has been mainly performed by a robotic
arm-mounted linear accelerator [31] which utilizes pre-
diction and correlation models [32–34] in order to
relate the external breathing signals to 3D tumor motion
(Cyberknife Synchrony, Saunnyvale, CA).
The aim of this study was to investigate the pos-
sible dosimetric advantages of using a tumor tracking
approach compared with the ITV concept to account
for respiratory-induced pancreatic tumor motion dur-
ing gantry-based SBRT. For a better estimation of the
dose in the moving tumor, we implemented 4D dose
calculation of SBRT treatments with the ITV [25, 35]
and the tumor tracking approach [25, 36, 37]. This allows
to include respiratorymotion effects into the evaluation of
both motion managements strategies, which has not been
done before so far for pancreatic tumors. Additionally, the
differences between the 3D and 4D dose calculations were
evaluated for both motion management strategies.
Methods andmaterials
Patients and four-dimensional computed tomography data
Four-dimensional computed tomography (4DCT) data,
from 12 consecutive patients with pancreatic cancer, was
included in this retrospective study. Among them, three
had undergone total duodenectomy. Each patient had
received a 4DCT scan using the SOMATOM Definition
AS Open (Siemens AG, Germany) CT scanner. Scans
were acquired under free breathing without coaching and
with respiratory monitoring (RPM, Varian Medical Sys-
tems, Palo Alto CA). An average CT and ten respiratory
phase CTs were reconstructed. For all but two patients
amplitude-sorted 4DCT scans had been obtained, while
for two patients phase-sorted 4DCT scans. The data
sets were transferred to Eclipse Treatment Planning Sys-
tem (Varian Medical Systems, Palo Alto). Slice thickness
of the 4DCT scans was 2mm and a pitch of 0.09 was
used.
Organ and target segmentation
The gross tumor volume (GTV) and multiple abdominal
organs were contoured manually by the radiation
oncologists of the Radiation Oncology Department of
University Hospital Zurich on one respiratory phase of
the 4DCT image set. This contouring phase, which is
approximately between inhale and exhale, was considered
to better approximate the average tumor position during
the full breathing cycle [14]. The following abdominal
organs were considered as organs at risk (OAR): duode-
num, stomach, bowel, left and right kidneys, liver and
spinal cord.
Karava et al. Radiation Oncology  (2017) 12:175 Page 3 of 9
Two individual structure sets were generated to simu-
late treatment planning for dynamic motion compensa-
tion with tumor tracking and for the conventional motion
encompassing ITV concept. For tracking, the structures
on the contouring phase were used with the GTV as
primary target volume (GTVtrack). For the ITV concept,
structure propagation was performed to all respiration
phases of the 4DCT image set by deformable registration
using MIM Maestro (v6.1, MIM Software Inc., Cleve-
land, OH). The individual structures from all phases were
combined to a total structure, which was then used for
treatment planning. The motion envelope enclosing all
GTVs was defined as ITV. The OARs were also created
from their motion envelope over all respiratory 4DCT
phases. An ITV-to-PTV margin of 5 mm was added for
the PTVitv. For tracking, a fixed 5mm-margin was added
to GTVtrack to form the PTVtrack .
Tumor motion
The center-of-volume motion for GTV at each respi-
ratory phase along the superior-inferior (SI), anterior-
posterior (AP), and left-right axes was measured using
MIM software. The tumor motion per direction was
determined as the maximal displacement. Three dimen-
sional tumor motion vector was defined as: 3D tumor
motion= (LR2 + AP2 + SI2)1/2.
Treatment planning - three dimensional (3D) dose
calculation
For both concepts, ITV and tracking, stereotactic body
radiotherapy (SBRT) was planned based on the concept-
specific structure sets. SBRT was planned using a nominal
energy of 10 MV photon beam in flattening-filter-
free mode. Two full arcs with collimator rotations of
5◦ and 355◦ were used. Treatment plan optimizations
for volumetric-modulated arc therapy (VMAT) and dose
calculations using the Analytical Anisotropic Algorithm
(AAA) 13.6.23 were performed in Eclipse Treatment
Planning System. The treatment plans were calculated on
the average reconstruction of the 4DCT data set for the
ITV concept and on the contouring phase for the tumor
tracking concept. The derived dose distribution is referred
from now on as 3D dose distribution.
A dose of 25 Gy in 5 fractions was prescribed to the
60%-isodose surrounding the PTV, which is now widely
used [6, 8], corresponding to a maximum allowed dose
of up to 41.5 Gy (166% of the prescribed dose). Treat-
ment plans were created with more than 95% of the PTV
receiving the prescribed dose. A risk adapted prescription
similar to the Simultaneous Integrated Protection (SIP)
concept of Gkika et al. was used [38]. Parts of the PTV
overlapping with OARs received between a minimum of
25 Gy and a maximum of 27.5 Gy. However, in the parts
of the PTV not overlapping with OAR, we were aiming
for a minimum dose of 27.5 Gy escalating the dose in the
GTV as high as 41.5 Gy. The constraints for OARs were
Dmax < 25 Gy on the spinal cord, Dmax < 27.5 Gy for the
bowel, the duodenum, the stomach and Dmean < 10 Gy
for the kidneys.
Four dimensional (4D) dose calculation
Inter-fractional and intra-fractional anatomical variations
can introduce significant errors in dose delivered by
radiation therapy. The impact of respiratory motion
should not be ignored as respiration can induce both rigid
body translation/rotation and organ deformation. The 3D
dose distribution does not fully represent the dose accu-
mulated by a moving tumor [25]. 4D dose calculation
considers the changing beam aperture and the changing
anatomy. It strongly depends on the patient’s respira-
tory cycle and therefore should be performed explicitly
on a patient-specific base. In this study, for the 4D dose
calculation, we used the concept presented by Ehrbar
et al. [25].
The respiratory cycles of all the patients were divided
into 10 breathing phases, according to the 4DCT. The
original treatment plans (for ITV and tumor tracking con-
cept) were divided into angular segments, which were
temporally assigned to the breathing phases. This pro-
cedure was done by using in-house MATLAB scripts
[25, 39].The created sub-plans were imported back to the
treatment planning system and calculated on the different
breathing phase. For the tumor tracking concept, the sub-
plans were calculated on the different phase CT image
set while the beam isocenter was shifted according to the
current center of volume position for the GTV to sim-
ulate adaptive motion compensation. Subsequently, 4D
dose accumulation was performed in MIM Software.
The dose accumulation was performed against the ini-
tial contouring phase and the other CT phases were
registrated to this one phase using deformable image reg-
istration. Following, the dose distributions at other phases
were summed up to the dose distribution at reference CT
to make 4D dose accumulation [39]. The resulting accu-
mulated 4D dose distributions were recorded for the GTV
volume and the OARs of the reference phase.
PTV size and dosimetric comparisons
The two motion-management techniques were compared
regarding the resulting PTV size, dose coverage of the
tumor, and sparing of organs at risk. The dosimetric com-
parisons were performed in 3D and 4D. For the 3D dose
comparison, the dose parameters were evaluated on the
structures used for treatment planning. Dose parameters
for the target (GTVtrack and ITV, respectively) include the
minimum (Dmin), maximum (Dmax), mean dose (Dmean),
D2, D95 and D98 - the dose received by 2, 95 and 98% of
the target volume. For OARs, two dose parameters were
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recorded: the Dmean and the D0.1cc, which corresponds to
the dose received by 0.1 cc of the volume. For the compar-
ison of 4D dose distributions, the same dose parameters
were evaluated within the structures delineated on the ref-
erence phase for the dose accumulation. This means that
for both motion-management techniques, the 4D target
dose parameters were evaluated on the GTV.
Statistical analysis
Dosimetric comparisons between ITV concept and tumor
tracking concept were performed with a two-sided
Wilcoxon paired signed rank test, with p-values < 0.05
considered significant. The degree of association between
the differences in dose parameters and the 3D tumor
motion was calculated by Spearman’s rank correlation
and a significance level of 5% was used (p-value < 0.05).
Statistical analysis was performed using R v.3.2.4 [40].
Results
Tumor motion and PTV size
The respiratory-induced pancreaticmotion was studied in
12 patients (Table 1). For all patients, the largest ampli-
tude of pancreatic motion was found in the SI direction.
The 3D motion ranged from 1.3 to 11.2 mm. With an
adaptive tumor tracking approach, the PTV size could be
significantly (p < 0.01) reduced with an average reduction
of 16.8% (Table 1). Figure 1 shows the linear regression
between PTV reduction and 3D motion. The values are
moderately correlated (rho = −0.46, p = 0.131).
Treatment plan quality
The reduction of PTV size allowed for a decrease of the
overlap between the PTV and duodenum. This improved
not only OAR dose sparing but also facilitated treatment
planning optimization. For five patients (3, 9, 10, 11 and
12) not all the optimization objectives could be satisfied
in the ITV treatment plan. For these five cases we had
to comprise on the dose to the overlapping part of ITV
and OARs (ITV-OAR), where we aimed for a dose of
37.5 Gy to 95% of the overlapping volume. Instead, this
volume was compromised to values between 83.5% and
93.9% for these five patients. However, the optimization
objectives were fulfilled for all patients using the tumor
tracking concept.
Comparisons of 3D and 4D dose calculations
In Table 2, the two motion management techniques are
compared using dosimetric parameters of the 3D and 4D
dose calculations. The target dose parameters are addi-
tionally shown in Fig. 2. There is a clear dosimetric advan-
tage for tumor tracking, regarding the tumor coverage
(D95%) in both, 3D and 4D dose calculation. Additionally,
many of the OAR dose parameters such as duodenum,
stomach, and liver Dmean showed a significant improve-
ment with tracking in 3D and 4D dose. There were also
cases in which significant OAR dose reduction was only
observed in the 4D dose distribution (bowel, left and
right kidney Dmean), or the 3D dose distribution (bowel
D0.1cc). Furthermore, highly correlated (rho ≥ 0.71), in
Table 1 Magnitude of pancreatic motion during respiration and PTV size for ITV and tumor tracking concept
Respiratory-induced motion amplitude (mm)
Patient PTVITV (cm3) PTVTracking (cm3) AP SI LR 3D Motion
1 54.3 33 2.4 10.4 3.3 11.2
2 146.2 122.4 3.0 5.1 0.6 5.9
3 236.7 200.9 2.0 4.3 1.6 5.1
4 109.8 90.2 1.0 3.7 0.7 3.9
5 154.9 147.6 0.7 1.1 0.3 1.3
6 34.9 28.2 0.5 4.6 1.1 4.7
7 83.0 70.6 1.0 1.6 0.8 2.1
8 114.6 90.4 6.1 1.9 1.7 6.6
9 241.4 209.6 1.8 7.6 1.2 7.8
10 244.0 208.4 1.9 4.3 0.3 4.8
11 177.6 163.9 1.3 5.0 0.5 5.2
12 116.3 95.5 2.1 7.4 3.5 8.5
Median 131.3 109.0 1.9 4.5 1.0 5.2
(prctiles) (96.4, 207.2) (80.4, 182.4) (1.0, 2.3) (2.8, 6.3) (0.6, 1.7) (4.3, 7.2)
Mean 142.8 121.7 2.0 4.8 1.3 5.6
SD 71.2 64.6 1.5 2.7 1.1 2.7
AP = anterior-posterior; SI = superior-inferior; LR = left- right plane; 3D = three dimensional; prctiles = (25-percentile, 75-percentile); SD = standard deviation
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Fig. 1 Linear regression between PTV reduction (%) and 3D tumor
motion [Equation: y=-2.28*(3D motion)-4.09, R2 = 0.541]
absolute values, and significant (p < 0.05) relationships
were observed between the 3D dose difference (3DTracking
− 3DITV ) and the 3D tumor motion for the bowel Dmean
(rho = −0.73) and the target volume Dmean (rho =
0.73). No significant results were found for the correlation
coefficients investigating the 4D dose differences.
Figure 3 shows dose-volume histograms (DVHs) for 3D
and 4D dose calculations. The data is presented for two
typical patients, patient 1 with pancreatic motion 11.2
mm and patient 7 with pancreatic motion 2.1 mm. For
patient 1 there is an obvious gain in the dose coverage
of the tumor and OAR dose sparing with tumor tracking
approach. However, for patient 7 minimal improvements
were observed regarding the tumor coverage and the OAR
dose reduction. Additionally, using the ITV concept for
patient 1 the 3D dose results in an overestimation for all
OARs in comparison with 4D dose calculation. On the
other hand, for the same patient using the tumor track-
ing approach almost no difference between the two dose
calculations is noticed with the exception for the dose to
the duodenum.
Discussion
In the present study we investigated the potential dosimet-
ric benefits of using the tumor tracking concept instead
of the ITV concept for the respiratory-induced motion
of pancreatic tumors. Tumor motion ranged between 2
and 11 mm. Planning target volumes were reduced using
the tracking approach with increasing tumor motion.
For tumor tracking all 3D plans fulfilled the constraints
whereas for the ITV concept we had to compromise the
PTV coverage in five cases. Mean and maximum doses to
most organs at risk were significantly reduced using tumor
tracking. However, using 4D calculation this significant
reduction could only be confirmed for the mean doses to
the organs at risk.
Our motion results have shown that the magnitude of
motion is largest in the SI direction and are in agreement
with previous studies with 4DCT. Tai et al. [41], Lens et al.
[42], and Hallman et al. [14] found a mean tumor motion
between 5 and 8 mm in SI direction. However, in the
literature larger pancreas motion has been also reported.
Particularly, Minn et al. [43] calculated on a planning
4DCT the range of centroid movement in SI direction
between 0.9 to 28.8 m (from the maximum inspiration
to the maximum expiration). Similar large motion ampli-
tudes were reported by Bussels et al. [10] and Feng et al.
[9] using MRI imaging. Observed differences in the pan-
creatic tumor motion between the current work and the
previous studies may be due to patient heterogeneity and
variation of inter-fractional pancreatic motion [41].
When the ITV concept is used, a large volume is unnec-
essarily irradiated since the whole envelope of motion is
treated. This can be avoided if the tumor tracking is con-
sidered. Our findings with the tumor tracking approach
led to a mean PTV volume reduction of 16.8% ± 8.4%
(range: −4.7 to −39.2%). This significant reduction of
the PTV is in agreement with the result found by Lens
et al.[44] using the midventilation approach as a motion
management technique for the pancreatic tumors. They
found a mean absolute PTV volume reduction of 13.9%.
However, it is worth mentioning that this single-phase
tracking is able to deposit higher dose to target volume
than the midventilation approach.
Tumor tracking allowed fulfilling all planning objectives
whereas for five ITV plans we had to make a compro-
mise on the PTV coverage in order to spare the organs
at risk adequately. Therefore, we consider tracking as a
promising tool for complicated cases for which the objec-
tives cannot be fulfilled using the ITV concept. Similarly,
for tracking of lung tumors Ehrbar et al. [25] showed a
significant reduction in the mean dose to the lung com-
pared to the ITV concept.
The 4D dose calculation can be considered as an appro-
priate tool for better understanding of the differences
between a static 3D dose distribution and taking the
respiratory motion into account. 4D dose calculation has
been also performed by other authors [25, 35–37, 45]
but mostly for lung [25, 37, 45] and not for pancreas.
The results of our study have shown that the 3D dose
distribution adequately represented the actual 4D dose
for the mean tumor dose as well as the coverage of the
tumor for both concepts. This is different compared to
investigations for the lung, where the 3D dose calculation
underestimates the dose to the tumor compared to the
actual 4D calculation for the ITV concept [25, 45]. This
difference is due to the changing density in the lung, which
is not that pronounced in the pancreatic region.
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Table 2 Comparison of the ITV and tracking concept
Dp [Gy] Median
3DITV
[Gy]
Median (prctiles) [Gy]
3DTracking − 3DITV
p-value Median
4DITV
[Gy]
Median (prctiles) [Gy]
4DTracking − 4DITV
p-value
TV GTV
Dmean 38.00 0.94 (0.39 to 1.09) < 0.05 38.08 0.27 (–0.16 to 0.55) 0.233
Dmax 41.55 0.01 (–0.13 to 0.04) 0.791 41.85 –0.27 (–0.98 to 0.14) 0.064
Dmin 24.59 0.75 (–0.07 to 1.98) < 0.05 24.83 0.34 (0.19 to 2.00) 0.064
D95 29.02 3.70 (1.19 to 5.51) < 0.05 30.87 1.56 (0.65 to 2.43) < 0.05
D2 40.87 0.05 (–0.11 to 0.20) 0.677 41.25 -0.27 (-0.81 to -0.04) < 0.05
D98 26.20 3.45 (1.24 to 5.30) < 0.05 27.78 1.73 (0.77 to 2.25) < 0.05
Bowel
Dmean 4.42 –0.27 (–0.56 to –0.06) 0.092 5.01 –0.45 (–0.58 to –0.24) < 0.05
D0.1cc 26.87 –1.34 (-1.51 to –0.73) < 0.05 26.20 –0.60 (–1.14 to 1.11) 0.791
Duodenum
Dmean 9.95 –1.13 (–1.53 to –0.93) < 0.05 10.45 –1.30 (–1.59 to 0.62) < 0.05
D0.1cc 27.31 –0.43 (–0.82 to –0.03) 0.164 27.97 0.46 (–1.41 to 0.63) 0.910
Stomach
Dmean 3.34 –0.39 (–0.80 to –0.08) < 0.05 3.38 –0.30 (–0.60 to –0.07) < 0.05
D0.1cc 23.57 –1.04 (–2.17 to –0.03) < 0.05 22.62 –0.11 (–1.11 to 0.97) 0.791
Liver
Dmean 2.04 –0.17 (–0.37 to -0.12) < 0.05 2.15 –0.18 (–0.35 to -0.07) < 0.05
Left Kidney
Dmean 3.89 –0.21 (–0.60 to 0.18) 0.266 3.58 –0.29 (–0.60 to -0.15) < 0.05
Right Kidney
Dmean 3.90 –0.24 (–0.46 to 0.16) 0.176 4.00 –0.40 (–0.57 to 0.12) < 0.05
Spinal Cord
Dmax 9.24 –0.31 (–1.10 to 0.47) 0.569 9.26 –0.37 (–1.55 to 0.56) 0.569
Dp: Dose parameter, prctiles = (25-percentile, 75-percentile), Target volume (TV): (ITV concept); GTV (tumor tracking).
Differences of the dose parameters for tumor volume and organs at risk after 3D and 4D dose calculation are given
In our study a single 4DCT was acquired per patient
and based on this, we performed our treatment plan-
ning. However, it has been shown that the respiratory-
induced tumor motion in pancreatic cancer patients given
by a single 4DCT is not necessarily representative of the
amplitude during treatment [42]. Furthermore, during
the treatment of pancreatic tumors, non-rigid shape and
position variations occur frequently both in the tumor and
the OARs [31]. These effects were not considered in this
work as structure delineation and 4D dose calculations
were based on a single 4DCT before the treatment. Res-
piratory patterns reproducibility during the imaging and
delivery is an important issue that needs further investi-
gation [20]. Such changing breathing and motion patterns
are not an issue for adaptive tracking approaches which
use real-time position feedback of the tumor, since they
are able to adapt to the actual tumor position during
delivery and this improves the daily both tumor coverage
and OAR sparing.
Another limitation of the study was that we assumed
perfect tumor tracking. We wanted to show what is pos-
sible with a perfect system rather than evaluating possible
current systems. We assumed that generating the PTV
with a 5 mm safety margin on the ITV/GTV, may be
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adequate to account for tracking errors, residual organ
deformation and rotation [46]. However, we performed
4D dose calculation which deals with the main con-
tributors of tracking inaccuracies such as rotation and
deformation [47].
Our results indicate that there is a possible benefit of
using tumor tracking approach instead of ITV concept
in SBRT treatment for pancreatic cancer patients. How-
ever, further investigation is needed in order to relate the
present results to clinical outcome in terms of toxicity.
This study showed that the tumor motion differs between
patients, indicating that tumor motion should be assessed
individually. Furthermore, the tumor tracking approach
resulted in better tumor coverage and a significant reduc-
tion of PTV facilitating subsequently treatment planning
and decreasing mean doses of OARs.
Conclusions
Taking the pancreatic tumor motion into account is
important and critical in SBRT. If this movement is
neglected, it could offset the potential benefits of SBRT.
In this study two motion management techniques, ITV
concept and tumor tracking concept, were evaluated
and compared to each other using 3D and 4D dose
calculations.
The dosimetric comparisons showed that the dose
benefit is patient andOAR specific. Tumor tracking might
be considered for patients in whom the planning objec-
tives with ITV concept cannot be met. However, tumor
tracking requires a 4D dose calculation to have an accurate
estimation of the doses to the organs at risk and addition-
ally, a suitable position information and motion compen-
sation system.
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